Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.5% – Should You Sell?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded down 5.5% during mid-day trading on Monday . The stock traded as low as $434.02 and last traded at $433.0790. 338,607 shares were traded during mid-day trading, a decline of 66% from the average session volume of 992,548 shares. The stock had previously closed at $458.12.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Stifel Nicolaus lifted their target price on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Oppenheimer restated an “outperform” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Evercore ISI increased their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research report on Thursday, September 11th. Finally, Barclays raised their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Twenty-three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $482.17.

Alnylam Pharmaceuticals Stock Performance

The business has a 50-day simple moving average of $454.49 and a 200 day simple moving average of $405.65. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market cap of $53.43 billion, a PE ratio of 1,685.25 and a beta of 0.30.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,650 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,675,409.21. This trade represents a 19.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 60,328 shares of company stock valued at $27,288,993. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. OFI Invest Asset Management boosted its holdings in Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 22 shares during the period. Howard Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.9% during the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after purchasing an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares during the period. Coastal Bridge Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 25 shares in the last quarter. Finally, Meridian Financial Advisors LLC increased its stake in Alnylam Pharmaceuticals by 3.5% during the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 28 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.